Syndivia
Manufacturing · France · 1-10 Employees
View Company Info for Free
Overview
Headquarters
8 Allée Gaspard Monge, Strasbourg, Grand...Phone Number
+33 367104220Website
www.syndivia.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About Syndivia
Syndivia is dedicated to advancing cancer treatment through its innovative GeminiMab ADC platform, which enables the creation of site-specific hinge-conjugated antibody-drug conjugates (ADCs) with optimized drug-to-antibody ratios. The GeminiMab Technology allows for the development of efficient and well-tolerated ADCs, enhancing antitumor efficacy for cancer patients. The company focuses on proprietary and partnered programs targeting various cancers, including prostate cancer and KRAS-mutant solid tumors. Syndivia actively protects its technologies through a robust intellectual property portfolio, ensuring a unique market position.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Syndivia your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once Syndivia has new funding data
Click to see if Syndivia had a recent Job posting/layoffs
Earning: See what the market has to say on Syndivia recently announced quarterly report
Check if Syndivia has recently received funding, and reach out quickly before it becomes old news!
Check out if Syndivia is spiking on competitors!
Syndivia, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at Syndivia
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when Syndivia launches new products
Recommended Actions
Find VP level buyers at Syndivia
Find 3 more new buyers
Company Profile Activity
Activity Insights
Syndivia is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Syndivia is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Syndivia.
Syndivia financials insights
Gather financial insights about Syndivia, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2019
Private Equity
$1.1M
2020
Other Financing Round
$2.3M
Syndivia Tech Stack
A closer look at the technologies used by Syndivia
Most Recent Scoops
Event
will be attending the 2022 BIO International Convention conference as an exhibitor. The event will occur from June 13 to June 16, 2022.
Funding
Funding
Funding
Funding
Funding
Syndivia News & Media
Syndivia Raises €2m in Financing
Syndivia, a Strasbourg, France-based research-driven biotechnology company focused on the development of new therapeutic modalities for cancers, raised €2m in deep tech financing from Bpifrance. The proceeds will be used to further fund the advancement of one company’s drug candidate towards the clinic. Led by Sasha Koniev, CEO, Syndivia is a biotechnology company that is […] The post Syndivia Raises €2m in Financing appeared first on FinSMEs.Syndivia Receives €2m Deeptech Financing From Bpifrance to Advance Its Lead Immunoconjugate for Solid Cancers
Syndivia, a research-driven biotechnology company focused on the development of new therapeutic modalities for cancers, announced today that it will benefit from €2 m deep tech financing from Bpifrance. Proceeds will be used to further fund the advancement of one company's drug candidate towards the clinic.Syndivia In-Licenses DARx Technology for 1-to-1 Linkage of Antibodies and Payloads for Preparation of New Classes of Biologics
Syndivia receives the exclusive license from SATT Conectus to DARx technology, which allows them to generate monodisperse 1-to-1 conjugates starting from off the shelf protein substrates (e.g., therapeutic antibodies). Antibody-drug and antibody-oligonucleotide conjugates with a degree of conjugation of 1 (DAR1), obtained using DARx, were demonstrated to have improved therapeutic indexes due to improved PK/PD parameters.Syndivia In-Licenses Novel Antibody Against Tumor-Specific Form of CD146 From SATT Sud-Est
STRASBOURG and MARSEILLE, France, Jan. 16, 2020 /PRNewswire/ -- Syndivia, a biotechnology company focused on the development of new therapeutic modalities for solid cancers based on specific targeting of the tumor microenvironment and anatomical hallmarks, announced today that it has been...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Syndivia
Sign Up For FreeTo access detailed company insights
Syndivia is dedicated to advancing cancer treatment through its innovative GeminiMab ADC platform, which enables the creation of site-specific hinge-conjugated antibody-drug conjugates (ADCs) with optimized drug-to-antibody ratios. The GeminiMab Technology allows for the development of efficient and well-tolerated ADCs, enhancing antitumor efficacy... Read More
